DrugPatentWatch Database Preview

Peginterferon alfa-2b - Biologic Drug Details

Email this page to a colleague

Summary for peginterferon alfa-2b

Tradenames:	2
Patents:	37
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for peginterferon alfa-2b

Recent Clinical Trials for peginterferon alfa-2b

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Shanghai Zhongshan Hospital	Phase 1/Phase 2
Shanghai Cancer Hospital, China	Phase 2
Icahn School of Medicine at Mount Sinai	Phase 2

See all peginterferon alfa-2b clinical trials

Pharmacology for peginterferon alfa-2b

Ingredient-type	Interferon Alfa-2b Interferon-alpha

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

General brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for peginterferon alfa-2b Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for peginterferon alfa-2b Derived from Company Disclosures

These patents were extracted from company disclosures

Glossary

Subscribe to access the full database, or Free Forever Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Number	Approval Date	Patent No.	Assignee	Estimated Patent Expiration	Status	Orphan	Source
Schering	PEGINTRON	peginterferon alfa-2b	VIAL	103949	001	2001-01-19	⤷ Free Forever Trial	Schering Corporation (Kenilworth, NJ)	2015-11-02	RX		company
Schering	PEGINTRON	peginterferon alfa-2b	VIAL	103949	001	2001-01-19	⤷ Free Forever Trial	Enzon, Inc. (Piscataway, NJ)	2013-11-10	RX		company
Schering	PEGINTRON	peginterferon alfa-2b	VIAL	103949	001	2001-01-19	⤷ Free Forever Trial	Enzon, Inc. (Piscataway, NJ)	2013-11-10	RX		company
Schering	PEGINTRON	peginterferon alfa-2b	VIAL	103949	001	2001-01-19	⤷ Free Forever Trial	Schering Corporation (Kenilworth, NJ)	2015-11-02	RX		company
Schering	PEGINTRON	peginterferon alfa-2b	VIAL	103949	001	2001-01-19	⤷ Free Forever Trial	Schering Corporation (Kenilworth, NJ)	2018-03-26	RX		company
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Number	>Approval Date	>Patent No.	>Assignee	>Estimated Patent Expiration	>Status	>Orphan	>Source

3) Low Certainty: US Patents for peginterferon alfa-2b Derived from Patent Text Search

These patents were identified by searching patent claims